Journal of Antimicrobial Chemotherapy

Leading articles:

SG Amyes and RS Miles

Extended-spectrum beta-lactamases: the role of inhibitors in therapy
J. Antimicrob. Chemother. 1998 42: 415-417; doi:10.1093/jac/42.4.415 [PDF] [Request Permissions]  

Original articles:

M Gazouli, LS Tzouvelekis, AC Vatopoulos, and E Tzelepi

Transferable class C beta-lactamases in Escherichia coli strains isolated in Greek hospitals and characterization of two enzyme variants (LAT-3 and LAT-4) closely related to Citrobacter freundii AmpC beta- lactamase
J. Antimicrob. Chemother. 1998 42: 419-425; doi:10.1093/jac/42.4.419 [Abstract] [PDF] [Request Permissions]  

E Sakagawa, M Otsuki, T Ou, and T Nishino

In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem
J. Antimicrob. Chemother. 1998 42: 427-437; doi:10.1093/jac/42.4.427 [Abstract] [PDF] [Request Permissions]  

KG Davey, A Szekely, EM Johnson, and DW Warnock

Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans
J. Antimicrob. Chemother. 1998 42: 439-444; doi:10.1093/jac/42.4.439 [Abstract] [PDF] [Request Permissions]  

O Cirioni, A Giacometti, F Barchiesi, and G Scalise

In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii
J. Antimicrob. Chemother. 1998 42: 445-451; doi:10.1093/jac/42.4.445 [Abstract] [PDF] [Request Permissions]  

J Pratten, AW Smith, and M Wilson

Response of single species biofilms and microcosm dental plaques to pulsing with chlorhexidine
J. Antimicrob. Chemother. 1998 42: 453-459; doi:10.1093/jac/42.4.453 [Abstract] [PDF] [Request Permissions]  

KE Bowker, HA Holt, RJ Lewis, DS Reeves, and AP MacGowan

Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans
J. Antimicrob. Chemother. 1998 42: 461-467; doi:10.1093/jac/42.4.461 [Abstract] [PDF] [Request Permissions]  

AG Vonk, MG Netea, NE Denecker, IC Verschueren, JW van der Meer, and BJ Kullberg

Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B
J. Antimicrob. Chemother. 1998 42: 469-474; doi:10.1093/jac/42.4.469 [Abstract] [PDF] [Request Permissions]  

JA Grandoni, PT Marta, and JV Schloss

Inhibitors of branched-chain amino acid biosynthesis as potential antituberculosis agents
J. Antimicrob. Chemother. 1998 42: 475-482; doi:10.1093/jac/42.4.475 [Abstract] [PDF] [Request Permissions]  

G Vrioni, C Nauciel, G Kerharo, and P Matsiota-Bernard

Treatment of disseminated Mycobacterium genavense infection in a murine model with ciprofloxacin, amikacin, ethambutol, clarithromycin and rifabutin
J. Antimicrob. Chemother. 1998 42: 483-487; doi:10.1093/jac/42.4.483 [Abstract] [PDF] [Request Permissions]  

FJ Schmitz, E Lindenlauf, B Hofmann, AC Fluit, J Verhoef, HP Heinz, and ME Jones

The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals
J. Antimicrob. Chemother. 1998 42: 489-495; doi:10.1093/jac/42.4.489 [Abstract] [PDF] [Request Permissions]  

C Lass-Florl, G Kofler, G Kropshofer, J Hermans, A Kreczy, MP Dierich, and D Niederwieser

In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis
J. Antimicrob. Chemother. 1998 42: 497-502; doi:10.1093/jac/42.4.497 [Abstract] [PDF] [Request Permissions]  

SR Norrby, AM Geddes, and PM Shah

Randomized comparative trial of cefpirome versus ceftazidime in the empirical treatment of suspected bacteraemia or sepsis. Multicentre Study Group
J. Antimicrob. Chemother. 1998 42: 503-509; doi:10.1093/jac/42.4.503 [Abstract] [PDF] [Request Permissions]  

P Biron, C Fuhrmann, H Cure, P Viens, D Lefebvre, A Thyss, M Viot, P Soler- Michel, C Rollin, and JJ Gres

Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer)
J. Antimicrob. Chemother. 1998 42: 511-518; doi:10.1093/jac/42.4.511 [Abstract] [PDF] [Request Permissions]  

TE Stephan, EO Ngo, P Ferrieri, JM Besser, and LM Nutter

Antimicrobial activity of the semisynthetic compound, hexahydrocolupulone
J. Antimicrob. Chemother. 1998 42: 519-522; doi:10.1093/jac/42.4.519 [Abstract] [PDF] [Request Permissions]  

K Weiss, M Laverdiere, and C Restieri

Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae
J. Antimicrob. Chemother. 1998 42: 523-525; doi:10.1093/jac/42.4.523 [Abstract] [PDF] [Request Permissions]  

JH Kim, JA Kang, Y Lee, KH Lee, JH Lee, EC Choi, and BK Kim

Susceptibility of penicillin-susceptible and -resistant pneumococci to CFC-222, a new fluoroquinolone
J. Antimicrob. Chemother. 1998 42: 527-530; doi:10.1093/jac/42.4.527 [Abstract] [PDF] [Request Permissions]  

M Cuenca-Estrella, JL Rodriguez-Tudela, E Mellado, JV Martinez-Suarez, and A Monzon

Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus
J. Antimicrob. Chemother. 1998 42: 531-533; doi:10.1093/jac/42.4.531 [Abstract] [PDF] [Request Permissions]  

E Miro, M del Cuerpo, F Navarro, M Sabate, B Mirelis, and G Prats

Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction
J. Antimicrob. Chemother. 1998 42: 535-538; doi:10.1093/jac/42.4.535 [Abstract] [PDF] [Request Permissions]  

JR Graybill, R Bocanegra, LK Najvar, MF Luther, and D Loebenberg

SCH56592 treatment of murine invasive aspergillosis
J. Antimicrob. Chemother. 1998 42: 539-542; doi:10.1093/jac/42.4.539 [Abstract] [PDF] [Request Permissions]  

Penetration of ceftazidime into bone from severely ischaemic limbs
J. Antimicrob. Chemother. 1998 42: 543-545; doi:10.1093/jac/42.4.543 [Abstract] [PDF] [Request Permissions]  

Letters:

H Schmidt, J von Maldeghem, M Frosch, and H Karch

Antibiotic susceptibilities of verocytotoxin-producing Escherichia coli O157 and non-O157 strains isolated from patients and healthy subjects in Germany during 1996
J. Antimicrob. Chemother. 1998 42: 548-550; doi:10.1093/jac/42.4.548 [PDF] [Request Permissions]  

S Mattar, L Sanchez, D Perez, A Arango, R Parodi, and C Muelle

In-vitro activities of cefepime and other beta-lactam antibiotics against clinical isolates from a Colombian teaching hospital
J. Antimicrob. Chemother. 1998 42: 550-552; doi:10.1093/jac/42.4.550 [PDF] [Request Permissions]  

M Tanaka, N Wada, SM Kurosaka, M Chiba, K Sato, and K Hiramatsu

In-vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin
J. Antimicrob. Chemother. 1998 42: 552-553; doi:10.1093/jac/42.4.552 [PDF] [Request Permissions]  

JM Hamilton-Miller and S Shah

In-vitro activity of a novel penem, Men 10700, against meningococci and gonococci, and the effect of a cysteine-containing supplement
J. Antimicrob. Chemother. 1998 42: 553-555; doi:10.1093/jac/42.4.553 [PDF] [Request Permissions]  

DM Johnson and RN Jones

In-vitro activity of a combination of two oral beta-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin
J. Antimicrob. Chemother. 1998 42: 555-557; doi:10.1093/jac/42.4.555 [PDF] [Request Permissions]  

DM Johnson, RN Jones, and MA Pfaller

Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia
J. Antimicrob. Chemother. 1998 42: 557-559; doi:10.1093/jac/42.4.557 [PDF] [Request Permissions]  

R Massa, C Bantar, M Mollerach, F Nicola, BE Murray, J Smayevsky, and G Gutkind

Emergence in vivo of resistance to ampicillin in a clinical isolate of Enterococcus hirae
J. Antimicrob. Chemother. 1998 42: 559-561; doi:10.1093/jac/42.4.559 [PDF] [Request Permissions]  

FJ Schmitz, B Hertel, B Hofmann, S Scheuring, J Verhoef, AC Fluit, HP Heinz, K Kohrer, and ME Jones

Relationship between mutations in the coding and promoter regions of the norA genes in 42 unrelated clinical isolates of Staphylococcus aureus and the MICs of norfloxacin for these strains
J. Antimicrob. Chemother. 1998 42: 561-563; doi:10.1093/jac/42.4.561 [PDF] [Request Permissions]  

BJ De Turck, MW Diltoer, PJ Cornelis, V Maes, HD Spapen, F Camu, and LP Huyghens

Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin
J. Antimicrob. Chemother. 1998 42: 563-564; doi:10.1093/jac/42.4.563 [PDF] [Request Permissions]  

R Luzzati, G Di Perri, D Fendt, D Ramarli, G Broccali, and E Concia

Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine
J. Antimicrob. Chemother. 1998 42: 565-566; doi:10.1093/jac/42.4.565 [PDF] [Request Permissions]  

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.